<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447368</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2015</org_study_id>
    <nct_id>NCT01447368</nct_id>
  </id_info>
  <brief_title>Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients</brief_title>
  <acronym>PROCEED</acronym>
  <official_title>Comparison of Medical Therapy (Oral Cinacalcet) Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, prospective randomized controlled study with the primary objective to&#xD;
      evaluate and compare medical treatment of severe SHPT, namely oral cinacalcet versus surgical&#xD;
      treatment, that is, parathyroidectomy with forearm autografting, on the progression of&#xD;
      coronary artery and valvular calcification and left ventricular mass index in endstage renal&#xD;
      disease patients receiving peritoneal dialysis over 12 months. The change in arterial&#xD;
      stiffening, left ventricular volume, aortic valve calcium score and bone mineral density,&#xD;
      nutritional status and biochemical parameters, quality of life measures will be evaluated as&#xD;
      secondary objectives of this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe secondary hyperparathyroidism (SHPT) are frequently complicated with&#xD;
      vascular calcification. There is some suggestion that subtotal parathyroidectomy may reduce&#xD;
      or stabilize vascular calcium scores in dialysis patients. Experimental data suggests that&#xD;
      SHPT plays an important role in mediating uraemic arterial disease and that parathyroidectomy&#xD;
      largely prevented the development of calcification. Cinacalcet has emerged as a novel therapy&#xD;
      for the treatment of SHPT and has been shown to reduce the need for surgical&#xD;
      parathyroidectomy. However, their effects on vascular, cardiac, bone and nutrition status&#xD;
      have not been evaluated and compared with parathyroidectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2010</start_date>
  <completion_date type="Actual">May 22, 2017</completion_date>
  <primary_completion_date type="Actual">May 22, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cinacalcet medical treatment versus total parathyroidectomy with forearm autografting surgical treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary artery calcium score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in coronary artery calcium score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in left ventricular mass index</measure>
    <time_frame>52 weeks</time_frame>
    <description>change in left ventricular mass index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular volume and ejection fraction</measure>
    <time_frame>52 weeks</time_frame>
    <description>change in left ventricular volume and ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic pulse wave velocity</measure>
    <time_frame>24 and 52 weeks</time_frame>
    <description>Change in aortic pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic valve and mitral valve calcium score</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in aortic valve and mitral valve calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in augmentation index and heart rate adjusted augmentation index</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>change in augmentation index and heart rate adjusted augmentation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in bone mineral density at forearm, spine and femur</measure>
    <time_frame>52 weeks</time_frame>
    <description>change in bone mineral density at forearm, spine and femur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>Kidney Disease Outcome Quality Initiatives (KDOQI QOL domain scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in resting energy expenditure</measure>
    <time_frame>24 and 52 weeks</time_frame>
    <description>Change in resting energy expenditure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lean muscle mass</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in lean muscle mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in handgrip strength</measure>
    <time_frame>24 and 52 weeks</time_frame>
    <description>Change in handgrip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective global assessment</measure>
    <time_frame>24 and 52 weeks</time_frame>
    <description>Change in subjective global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium and phosphorus</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Change in biochemical parameter Serum calcium and phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in intact parathyroid hormone (iPTH) level</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in biochemical parameter Parathyroid hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alkaline phosphatase</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Change in biochemical parameter alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum albumin</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>CHange in biochemical parameter serum albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lymphocyte count</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>change in lymphocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lipid profile</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>change in lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in systolic and diastolic blood pressure</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>change in systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in subendocardial viability ratio</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>change in subendocardial viability ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Kidney Failure</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Cinacalcet treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical total parathyroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily</description>
    <arm_group_label>Cinacalcet treatment</arm_group_label>
    <other_name>Regpara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical total parathyroidectomy with forearm autografting</intervention_name>
    <description>Surgical total parathyroidectomy with forearm autografting will be performed</description>
    <arm_group_label>Surgical total parathyroidectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ESRD patients on long-term peritoneal dialysis treatment, with elevated intact&#xD;
             parathyroid hormone (iPTH) levels &gt; 800pg/mL.&#xD;
&#xD;
          2. Patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound&#xD;
             imaging or radioisotope scan.&#xD;
&#xD;
          3. Patients with age between 18 - 75 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with background valvular heart disease&#xD;
&#xD;
          2. Patients who are unfit for general anaesthesia&#xD;
&#xD;
          3. Patients with acute myocardial infarction within recent two months&#xD;
&#xD;
          4. Patients with poor general condition&#xD;
&#xD;
          5. Patients with plans for living related kidney transplant within 1 year&#xD;
&#xD;
          6. Patients with previous history of parathyroidectomy&#xD;
&#xD;
          7. Patients with underlying malignancy&#xD;
&#xD;
          8. Patients with hepatic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hong Kong, Queen Mary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital and Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>secondary hyperparathyroidism</keyword>
  <keyword>parathyroidectomy</keyword>
  <keyword>vascular calcification</keyword>
  <keyword>cinacalcet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

